These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36156003)

  • 1. [Clonal Evolution in the Tumor Microenvironment].
    Ueda Y; Togashi Y
    Gan To Kagaku Ryoho; 2022 Sep; 49(9):907-913. PubMed ID: 36156003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant clonal evolution drives multiple myeloma cellular ecological diversity and microenvironment reprogramming.
    Liang Y; He H; Wang W; Wang H; Mo S; Fu R; Liu X; Song Q; Xia Z; Wang L
    Mol Cancer; 2022 Sep; 21(1):182. PubMed ID: 36131282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advancements in tumour microenvironment landscaping for target selection and response prediction in immune checkpoint therapies achieved through spatial protein multiplexing analysis.
    Andhari MD; Antoranz A; De Smet F; Bosisio FM
    Int Rev Cell Mol Biol; 2024; 382():207-237. PubMed ID: 38225104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B cell clonality in cancer.
    Bryushkova EA; Mushenkova NV; Turchaninova MA; Lukyanov DK; Chudakov DM; Serebrovskaya EO
    Semin Immunol; 2024 Mar; 72():101874. PubMed ID: 38508089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Adaptome as Biomarker for Assessing Cancer Immunity and Immunotherapy.
    Han J; Lotze MT
    Methods Mol Biol; 2020; 2055():369-397. PubMed ID: 31502161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy.
    Li L; Wang Y; Shi W; Zhu M; Liu Z; Luo N; Zeng Y; He Y
    Cancer Med; 2019 Dec; 8(18):7669-7678. PubMed ID: 31692284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer - An Insurgency of Clones.
    Gisselsson D; Egnell R
    Trends Cancer; 2017 Feb; 3(2):73-75. PubMed ID: 28718446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering chimeric antigen receptor-T cells for cancer treatment.
    Ye B; Stary CM; Li X; Gao Q; Kang C; Xiong X
    Mol Cancer; 2018 Feb; 17(1):32. PubMed ID: 29448937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harnessing Tumor Evolution to Circumvent Resistance.
    Pogrebniak KL; Curtis C
    Trends Genet; 2018 Aug; 34(8):639-651. PubMed ID: 29903534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs.
    Varn FS; Schaafsma E; Wang Y; Cheng C
    Cancer Res; 2018 Nov; 78(22):6413-6423. PubMed ID: 30254145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances for studying clonal evolution in cancer.
    Ding L; Raphael BJ; Chen F; Wendl MC
    Cancer Lett; 2013 Nov; 340(2):212-9. PubMed ID: 23353056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of clonal evolution in multiple myeloma.
    Furukawa Y; Kikuchi J
    Int J Hematol; 2020 Apr; 111(4):496-511. PubMed ID: 32026210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.
    Gnjatic S; Bronte V; Brunet LR; Butler MO; Disis ML; Galon J; Hakansson LG; Hanks BA; Karanikas V; Khleif SN; Kirkwood JM; Miller LD; Schendel DJ; Tanneau I; Wigginton JM; Butterfield LH
    J Immunother Cancer; 2017; 5():44. PubMed ID: 28515944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
    Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
    J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics.
    Nam AS; Chaligne R; Landau DA
    Nat Rev Genet; 2021 Jan; 22(1):3-18. PubMed ID: 32807900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies.
    Lo AA; Wallace A; Oreper D; Lounsbury N; Havnar C; Pechuan-Jorge X; Wu TD; Bourgon R; Jones R; Krogh K; Yang GY; Zill OA
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design.
    Diaz-Cano SJ
    Int J Mol Sci; 2012; 13(2):1951-2011. PubMed ID: 22408433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciphering the universe of genetic context-dependencies using mouse models of cancer.
    Falcomatà C; Bärthel S; Schneider G; Saur D; Veltkamp C
    Curr Opin Genet Dev; 2019 Feb; 54():97-104. PubMed ID: 31078084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput single-сell sequencing in cancer research.
    Jia Q; Chu H; Jin Z; Long H; Zhu B
    Signal Transduct Target Ther; 2022 May; 7(1):145. PubMed ID: 35504878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.